SHKRELI TRIAL GOES TO THE JURY

The Denver Post - - BUSINESS -

Ajury will re­sume de­lib­er­a­tions Tues­day at the fed­eral se­cu­ri­ties fraud trial of Martin Shkreli, shown ar­riv­ing at U.S. District Court on Mon­day with his at­tor­ney. The 34-year-old for­mer biotech CEO is no­to­ri­ous for buy­ing the rights to a drug called Dara­prim and promptly rais­ing the price by 5,000 percent, and for trolling his crit­ics on so­cial me­dia. The de­lib­er­a­tions fol­low about a month of tes­ti­mony in fed­eral court in New York City, most of it from in­vestors in two failed hedge funds run by the de­fen­dant. The defense ar­gued that the in­vestors weren’t vic­tims be­cause they re­couped their money when the drug com­pany went pub­lic.

Drew Angerer, Getty Images

Newspapers in English

Newspapers from USA

© PressReader. All rights reserved.